A case series using famciclovir in stem cell transplant recipients with valacyclovir hypersensitivity reactions
Shreya A Shah1, Alison Gulbis2, Kaci Wilhelm2
1Department of Pharmacy, NewYork-Presbyterian Hospital, New York, NY, USA sas9128@nyp.org.
Background:
Herpes simplex virus and varicella zoster virus reactivation can occur in up to 32% and 40% of patients, respectively in the first year post-transplant without prophylaxis. Antiviral therapy consisting of acyclovir or valacyclovir is recommended for at least 1 year post stem cell transplant per evidence-based guidelines.
Objective:
In the event of a contraindication or hypersensitivity reaction to either drug, an alternative is essential based on the proven efficacy in reducing clinically significant herpes simplex virus and varicella zoster virus reactivations. We report two cases of successful initiation of famciclovir in stem cell transplant recipients experiencing hypersensitivity to valacyclovir or acyclovir.
Discussion:
In both cases, there were no hypersensitivity reactions or breakthrough viral infections after famciclovir initiation but this observation is limited by a small patient population.
Conclusion:
Due to the limited data available, famciclovir appears to be a reasonable option in immunocompromised patients with a mild valacyclovir or acyclovir hypersensitivity reaction.
More Related Videos
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Cytomegalovirus Disease
Hypersensitivity Reactions: Immune-Complex Reactions
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Allergic Drug Reactions
Drug Toxicity: Allergic Reactions
